Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine Surveillance Following Treatment for Lung Cancer
Mené sur 133 patients atteints d'un cancer du poumon de stade IIA à IV, cet essai multicentrique évalue, par rapport à un suivi médical par examens d'imagerie, le bénéfice en termes de survie d'une surveillance post-traitement des symptômes des patients à l'aide d'un questionnaire en ligne
Symptom monitoring during chemotherapy via web-based patient-reported outcomes (PROs) was previously demonstrated to lengthen survival in a single-center study. A multicenter randomized clinical trial compared web-based monitoring vs standard scheduled imaging to detect symptomatic recurrence in patients with lung cancer following initial treatment. A planned interim analysis (9-month follow-up) found a significant survival benefit (19-month survival in the PRO group vs 12 months in the control group). We now present the final overall survival analysis.
JAMA , résumé, 2018